FormWeb • sacubitril-valsartan

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Add Formweb to your mobile device

Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

sacubitril-valsartan

sacubitril-valsartan

Formulary ARB combinations formulary

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Entresto	TABLET, ORAL	24 mg-26 mg, 49 mg-51 mg, 97 mg-103 mg

Comments:

Entresto is approved for sample use in HH Endocrinology and Diabetes Clinics.

Concomitant use or use within 36 hours of ACE inhibitors is contraindicated with ENTRESTO. Delay initiation of ENTRESTO until >36 hours after last dose of an ACE inhibitor. This does NOT apply to ARBs.

The pharmacists may automatically delay initiation of either ENTRESTO or an ACE inhibitor for 36 hours to avoid an overlap in therapies.

Reviewed: 25 August 2015 November 2020 (Entresto)

Last updated: Jan. 17, 2023

Black Box Warning: Valsartan: pregnancy risk
HAZ-MED: Group 3

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.